Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.55 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9347724 | 0.98 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL9347774 | 0.98 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL24614167 | 0.98 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL1687607 | 0.98 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL346786 | 0.95 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL7345698 | 0.95 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| Carbamic Acid SCHEMBL9681965 | 0.88 | RAB9A (0.48) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL6963172 | 0.87 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL7340276 | 0.87 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL6696545 | 0.84 | DRD2 (0.50) | CYP2A6ASIC3LOXL2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116646018-A | Method for predicting molecular composition of hydrocracking raw material | 浙江中控技术股份有限公司 | 2023-08-25 | — | — | CN | claimed |
| US-8497260-B2 | 2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient | Industry-University Cooperation Foundation Sogang University (KR) | 2013-07-30 | — | — | US | claimed |
| US-20100261727-A1 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | Industry-University Cooperation Foundation Sogang University | 2010-10-14 | — | — | US | claimed |
| CN-101857587-A | 2-aryl benzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and phrmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient | SGU HOLDINGS CO LTD | 2010-10-13 | — | — | CN | claimed |
| US-20030032779-A1 | Estrogen receptor ligands | OHMAN LARS (SE) | 2003-02-13 | — | — | US | claimed |
| EP-0980386-A2 | ESTROGEN RECEPTOR CRYSTALS AND LIGANDS | KARO BIO AB (SE) | 2000-02-23 | — | — | EP | claimed |
| WO-1998056812-A2 | ESTROGEN RECEPTOR CRYSTALS AND LIGANDS | KARO BIO AB (SE) | 1998-12-17 | — | — | WO | claimed |
| CN-116646018-A | Method for predicting molecular composition of hydrocracking raw material | 浙江中控技术股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-115403522-A | Biphenyl quinoline skeleton compound with C2 axis chirality, chiral isomer thereof, preparation method and application thereof | 中国科学院成都有机化学有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115403523-A | Biquinoline-aryl phenol framework compound with axial chirality and preparation method and application thereof | 中国科学院成都有机化学有限公司 | 2022-11-29 | — | — | CN | disclosed |
| WO-2021038581-A1 | A ONE STEP SYNTHESIS OF 2-SUBSTITUTED BENZO[B]THIOPHENES | INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IIT Madras) (IN) | 2021-03-04 | — | — | WO | disclosed |
| CN-110791775-B | Method for continuously preparing 2-aryl-benzothiophene/furan compounds by using electrochemical microchannel reaction device | 南京工业大学 | 2021-02-05 | — | — | CN | disclosed |
| US-10888545-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-01-12 | — | — | US | disclosed |
| WO-1996040693-A1 | PROCESS FOR THE SYNTHESIS OF VINYL SULFENIC ACID DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5569772-A | CHEMICAL INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5569772-A | CHEMICAL INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| EP-0729956-A1 | Benzothiophene compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1996002248-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996002248-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0671396-A1 | PROCESS FOR PRODUCING 2-SUBSTITUTED BENZO b]THIOPHENE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10888545-B2 | Compositions and methods for treating estrogen-related medical disorders | HSD17B11, SHBG, ESRRB | CYP2A6 127/4885ASIC3 2225/4885LOXL2 1576/4885 |
| US-20100261727-A1 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | APP, PSEN1, PSEN2 | CYP2A6 2559/4885ASIC3 4749/4885LOXL2 4249/4885 |
| US-20030032779-A1 | Estrogen receptor ligands | ESR1, ESRRB, GPER1 | CYP2A6 411/4885ASIC3 2023/4885LOXL2 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.